Genzyme inks $150M deal for Ceregene therapy

Genzyme has agreed to pay $25 million up front to partner with Ceregene on CERE-120, its experimental lead therapy being developed for Parkinson's disease. Genzyme has also signed up to pay up to $125 million in milestones as well as half of the late-stage development costs for the therapy. In return, Genzyme gets marketing rights outside the U.S. and Canada.

"We look forward to helping further the development of this exciting approach, building on our long-term commitment to gene therapy and neurodegenerative diseases," said David Meeker, president, Lysosomal Storage Disorders unit, Genzyme Corporation. "This program which is focused on preserving neuronal function will complement our existing Parkinson's clinical trial that is currently underway."

- check out the release on the deal

Related Articles:
Genzyme snares cancer therapy in $345M buyout. Report
Genzyme boosts AnorMED bid to $580M. Report
Genzyme sees big returns from small drug market. Report

Suggested Articles

Flagship Pioneering has raised $824 million for a fund to support biotech and health companies that have come up through its Flagship Labs foundry.

At the annual meeting of the American College of Cardiology this week, a new analysis of Merck’s anacetrapib cast a shadow on DalCor’s hypothesis

It’s a pretty good news day for NGM Bio: Merck doubled down on its R&D pact, and it’s nabbed a Genentech executive to help run its trials.